Theralase Technologies Inc. V.TLT

Alternate Symbol(s): V.TLT.WT | TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > 60% of the road = 270-days

<< Previous

Bullboard Posts

Next >>

Comment by ScienceFirston Jul 15, 2022 7:59am

200 Views

Post# 34826363

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:60% of the road = 270-days

Infinity ... Good points.

JV deal would probably not be signed before Roger is reinstated as a CEO, after Feb. 2023. He deserves to be back in that role, no doubt, given where he brought us (on the verge of a Breakthrough designation and next SOC).

JV would bring upfront payment, avoiding the need for a pp. Our Ph. 2 NMIBC data is worth approx. 600M$+ now, as per industry's standards.

That could then fund COVID-19 and NSCLC trials. And make no mistake; NSCLC is the big prize. Bigger than NMIBC.

<< Previous

Bullboard Posts

Next >>

How a junior advances one of the largest undeveloped diamond projects